» Articles » PMID: 25132074

Improved Hydroxyurea Effect with the Use of Text Messaging in Children with Sickle Cell Anemia

Overview
Date 2014 Aug 19
PMID 25132074
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In children with sickle cell anemia (SCA), hydroxyurea reduces morbidity, but adherence is frequently suboptimal. Because most families of children with SCA have access to cellular telephone services, we assessed the impact of text messaged reminders as a tool to improve adherence to hydroxyurea.

Procedure: All patients <19 years of age with HbSS or HbSβ(0) thalassemia who were treated with hydroxyurea at a maximal tolerated dosage (MTD) at St. Jude Children's Research Hospital Comprehensive Pediatric Sickle Cell Program and who received automated text message reminders (SIMON®) were retrospectively identified. Laboratory parameters, hospitalizations, and medication possession ratios (MPR) prior to and after initiation of SIMON® were compared to assess the impact of SIMON®.

Results: Of the 97.3% of families with access to a cell phone, 91% elected to receive text message reminders. Among 55 children receiving hydroxyurea at MTD, laboratory parameters reflected waning medication compliance during the 12 months prior to SIMON®. Following initiation of SIMON®, children had higher mean corpuscular volumes, hemoglobin levels and fetal hemoglobin percentages and lower absolute reticulocyte counts and bilirubin levels, suggesting improved medication adherence. Hospitalizations were uncommon before and after SIMON®, and medication possession ratios (MPRs) were high before and after SIMON®, neither was significantly changed.

Conclusions: SIMON® was feasible and improved hematologic parameters in children with SCA receiving hydroxyurea at a MTD. Future work will include extension of this technology to children with other chronic medical conditions who require daily use of medication.

Citing Articles

Comment on: "Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease": Participant evaluation.

Martin M, Smaldone A, Green N Pediatr Blood Cancer. 2024; 72(1):e31382.

PMID: 39394966 PMC: 11584301. DOI: 10.1002/pbc.31382.


Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease.

Walden J, Brown L, Seiguer S, Munshaw K, Rausch J, Badawy S PLoS One. 2024; 19(6):e0304644.

PMID: 38917111 PMC: 11198815. DOI: 10.1371/journal.pone.0304644.


Self-management interventions for children and young people with sickle cell disease: A systematic review.

Poku B, Atkin K, Kirk S Health Expect. 2023; 26(2):579-612.

PMID: 36597596 PMC: 10010100. DOI: 10.1111/hex.13692.


Development and Validation of the Patient/Caregiver Reported Hydroxyurea Evaluation of Adherence for Life (HEAL) Scale.

Janson I, Bloom E, Hampton K, Meier E, Rampersad A, Kronenberger W Patient Prefer Adherence. 2022; 16:3229-3239.

PMID: 36531301 PMC: 9749495. DOI: 10.2147/PPA.S387227.


Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study.

Badawy S, DiMartino L, Brambilla D, Klesges L, Baumann A, Burns E JMIR Form Res. 2022; 6(10):e41415.

PMID: 36240004 PMC: 9578525. DOI: 10.2196/41415.